NEXR-TECHNOLOGIES-SE
30.9.2021 18:49:09 CEST | Business Wire | Press release
NeXR Technologies SE (XETRA: NXR ) has reached one more milestone in its groundbreaking cooperation with H&Mbeyond. By installing the Fusion III body scanner developed by NeXR Technologies and starting the test phase of the AvatarCloud Fashion application, H&M Germany is opening selected stores for virtual fitting of its new collection. From 14 October to 6 November this year, H&M customers will have the opportunity to virtually try on perfect-fit looks from the new collection from home and outside of store opening hours via "digital fitting rooms" in two stores in Berlin and one H&M store in Hamburg.
As part of the test phase, customers can have a personal avatar, a digital twin, created free of charge with their exact body measurements in the scanners of participating H&M stores. The innovative AvatarCloud app from NeXR Technologies allows customers to try on the matching styles of around 30 pieces of apparel from the new collection on their own avatar. An expansion of the virtual fitting offer to further collections is already technically possible.
NeXR Technologies SE: H&M Germany opens selected stores for virtual fitting with AvatarCloud app
The technology, developed by NeXR and driven forward in collaboration with H&Mbeyond. for use in fashion retail, strives not only to offer an exciting digital shopping experience but also to analyze together with customers what impact "digital fitting rooms" can have on shopping behavior. H&Mbeyond. the Berlin-based innovation lab of H&M Germany, is responsible for developing and piloting innovative products and services relevant to H&M's global organization.
Markus Peuler, Managing Director of NeXR Technologies SE: "We are very proud that H&Mbeyond. awarded us as a trusted partner in their innovation work immediately with the test operation in three of their major stores. With our Virtual Fitting solution for H&M Germany, we have reached another milestone in the roll-out of our products announced for the current financial year. We are confident that this cooperation will also enable us to make a long-term contribution to sustainability in the textile industry. That is a very important matter for us."
The AvatarCloud app is available on the Apple AppStore and Google Play . For more information on AvatarCloud and the new H&M collection, please visit: avatar.cloud .
About NeXR Technologies
NeXR Technologies SE from Berlin (XETRA: NXR ) is a listed technology company with a focus on virtual reality applications. The core of the company consists of personalized, digital avatars that support users in performing everyday tasks more efficiently. These include the visualization of training successes on one's own avatar (NeXR Fitness), the virtual fitting of clothing (NeXR Fashion) or the participation in and the design of virtual live events (NeXR Show) and remote presentations (NeXR Seminar). NeXR Technologies has core competencies in 3D scanner development, motion capture, virtual reality, virtual production as well as deep understanding in gaming and data-based business models. Based on two self-developed multi-user and multi-purpose platforms, NeXR Technologies offers products and solutions for numerous user industries. NeXR Technologies SE is listed in the General Standard of the Frankfurt Stock Exchange. For more information, please visit www.nexr-technologies.com .
About H&M
H & M Hennes & Mauritz AB (publ) was founded in Sweden in 1947 and is quoted on Nasdaq Stockholm. H&M's business idea is to offer fashion and quality at the best price in a sustainable way. In addition to H&M, the group includes the brands COS, Monki, Weekday, & Other Stories, H&M HOME and ARKET as well as Afound. The H&M group has 51 online markets and more than 5,000 stores in 74 markets including franchise markets. In 2019, net sales were SEK 233 billion. The number of employees amounts to more than 179,000. For further information, visit hmgroup.com .
Language: |
English |
Company: |
NEXR Technologies SE |
Charlottenstraße 4 |
|
10969 Berlin |
|
Germany |
|
Phone: |
+49 (0) 30 403 680 143 |
Fax: |
+49 (0) 30 403 680 141 |
E-mail: |
|
Internet: |
|
ISIN: |
DE000A1K03W5 |
WKN: |
A1K03W |
Listed: |
Regulated Market in Berlin, Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005829/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom